This is a working overview of PT-141, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Those who have used topical corticosteroids over a prolonged period of time Those who have used corticosteroids to cover a large surface area Those with broken skin barrier or extensive abrasions Those who have recently undergone stress (such as illness, trauma, surgery) Children under the age of 12 HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment.
=== June === 1 June – Robert Anderson, cricketer (Otago, Central Districts, national team) (born 1948). 4 June Edwin Perry, politician, New Zealand First list MP (2002–2005), Masterton District Councillor (2007–2010) (born 1948). Bruce Stewart, lawyer, Rhodes Scholar (1975), King's Counsel (since 2000) (born 1953). 6 June – Marise Wipani, beauty pageant contestant, actor (Came a Hot Friday, Shortland Street, Soldier Soldier), and television presenter (Lotto) (born 1964). 7 June – David Lean, local politician, Mayor of New Plymouth (1980–1992), Taranaki Regional Councillor (since 1989) (born 1948). 8 June Anthony Reid, historian (Australian National University, UCLA, National University of Singapore) (born 1939). Stu Wilson, rugby union player (Wellington, national team) and television commentator (born 1954). 10 June – Roka Ngarimu-Cameron, tohunga raranga and traditional Māori arts academic (University of Otago) (born 1948). 12 June Maurice Gee, novelist (Under the Mountain, In My Father's Den, Plumb), Arts Foundation of New Zealand Icon (since 2003) (born 1931). Phil Silva, psychologist and paediatrician (University of Otago), founder (1972) and director (1972–1999) of the Dunedin Study (born 1940). Sir Cliff Skeggs, Hall of Fame businessman and local politician, Mayor of Dunedin (1977–1989) (born 1931). 14 June – Lorraine Barry, music manager (Dave Dobbyn, Ice-T, Spice Girls) (born c. 1958). 15 June – Barry Vercoe, computer scientist (Massachusetts Institute of Technology) and composer, inventor of Csound (1985) (born 1937).
=== Injection loop === The injection loop is a segment of tubing of known volume which is filled with the sample solution before it is injected into the column. Loop volume can range from a few microliters to 50 ml or more.
Sources: en.wikipedia.org
== Transportation == UPS operates over 119,000 delivery vehicles worldwide, ranging from bicycles to tractor-trailer trucks. In a long-running company policy to avoid advertisement or endorsement of a vehicle manufacturer, all external manufacturer emblems and badging are removed when a vehicle enters service (whenever possible). The typical lifespan of a UPS ground vehicle is 20–25 years (or more), lasting until the structural integrity is compromised. The company does not re-sell any of its ground vehicles. As such, retired vehicles are almost always stripped of reusable parts before being sent to be crushed/broken up. Prior to scrapping, UPS trucks and trailers have all company branding painted over and are assigned an ADA (Automotive Destruction Authorization) number and must be crushed under the supervision of UPS Automotive personnel, which records the vehicle's destruction. The only exception to this policy are vehicles taken off the road for internal company use; package cars (repainted white) are used for various purposes (typically at large hubs); older semi tractors sometimes see use as terminal tractors.
=== Internal social situation === The social situation in Mexico in the later years of the Lázaro Cárdenas presidency and the entirety of the Manuel Ávila Camacho presidency, was one of profound socio-economic inequality. By 1940, the upper class represented only 1.05% of the population, the middle class 15.87%, and the lower class 83.08%. Most of the Mexican population were farmers living in the countryside, and a working class was beginning to emerge from the emerging industrial development sector. To guarantee that there were institutions before the state that defended the interests of the workers of different sectors, various union organizations were established, including the Confederation of Mexican Workers (CTM), the Unión Sinarquista de Mexico, among others, which made up the Mexico left. The union leaders were the Communist Party of Mexico (PCM), representing the more radical left, and Vicente Lombardo Toledano and Fidel Velázquez Sánchez, representing the more moderate left. The right wing was represented by a broad conservative and pro-clerical sector, the business sector (especially financial and industrial), and the new National Action Party (PAN), founded in 1939 by Manuel Gómez Morín. The confrontations between left and right were a constant that caused violent conflicts. However, Cárdenas was able to achieve relative social stability before the war by championing union organizations and peasants, while accommodating conservatives by postponing social reforms.
On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir. Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion. On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp. On 26 March 2009, Roche acquired Genentech for $46.8 billion. On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990, after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto–based research facilities to its campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco. Genentech became a wholly owned subsidiary group of Roche on 25 March 2009. Roche began vacating the NJ site in 2012, and sold it off in 2016. Roche acquired Medingo Ltd. in April 2010, for $160 million and BioImagene, Inc. in August for $100 million. In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project. In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.
And while it had been speculated that the availability of such treatment options might change public perception of the risks associated with drug use and might lead to an increase in illicit drug use, the incidence of heroin abuse in Switzerland has declined sharply since the introduction of heroin-assisted treatment. As a study published in The Lancet concluded:
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.